FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1769-1770 December 5, 1996 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Stegeman, C. A. PubMed Citation

To the Editor: In their study of treatment with co-trimoxazole (trimethoprim–sulfamethoxazole) to prevent relapses of Wegener's granulomatosis (July 4 issue),¹ Stegeman et al. do not report the cumulative doses of cyclophosphamide and prednisolone in their two groups of patients during the study period. Although this omission does not undermine their conclusion, it is relevant because the information may shed light on the mechanism by which co-trimoxazole prevents relapses. If, as Stegeman et al. speculate, co-trimoxazole either prevents infections that would have triggered relapses or has a direct antiinflammatory effect, then one would expect a lower cumulative dose of immunosuppressive agents . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.